
    
      This is a non-significant risk multicenter, longitudinal specimen collection study. At the
      Baseline Visit, whole blood will be collected to be paired with either a previously collected
      tumor biopsy tissue sample or a prospectively collected tumor tissue sample. Whole blood
      samples will also be collected longitudinally at Interim visits for up to 5 years. Interim
      visits will be on a schedule dictated by their physician's standard-of-care management
      protocol. No more than 100mL of blood will be collected per month. Tumor tissue from
      recurrences will be collected for the duration of subject participation (after the Baseline
      Visit).
    
  